These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 25641902)

  • 21. Utility of the thromboplastin-plasma cell-block technique for fine-needle aspiration and serous effusions.
    Kulkarni MB; Desai SB; Ajit D; Chinoy RF
    Diagn Cytopathol; 2009 Feb; 37(2):86-90. PubMed ID: 19021217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
    Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
    Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomorphology, Immunophenotype, and cytogenetic profile of leukemic serous effusions.
    Kaur K; Patel T; Patra S; Trivedi P
    Diagn Cytopathol; 2021 Aug; 49(8):948-958. PubMed ID: 33973738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 2-year retrospective study on pleural effusions: A cancer centre experience.
    Valerio E; Nunes W; Cardoso J; Santos A; Bovolim G; Domingos T; De Brot L; Saieg M
    Cytopathology; 2019 Nov; 30(6):607-613. PubMed ID: 31306514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
    Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
    Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose transporter 1 protein detected by enzyme-linked immunosorbent assay and immunocytochemistry: a useful diagnostic tool for malignant pleural effusions.
    Liao ND; Chiang TA; Lee WY
    Cancer Cytopathol; 2013 Dec; 121(12):695-702. PubMed ID: 23861325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
    Welker L; Müller M; Holz O; Vollmer E; Magnussen H; Jörres RA
    Virchows Arch; 2007 Apr; 450(4):455-61. PubMed ID: 17377812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative analysis of conventional cytopreparatory and liquid based cytological techniques (Sure Path) in evaluation of serous effusion fluids.
    Dadhich H; Toi PC; Siddaraju N; Sevvanthi K
    Diagn Cytopathol; 2016 Nov; 44(11):874-879. PubMed ID: 27546351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with closed needle biopsy and pleural fluid cytology in the diagnosis of malignant pleural effusions in Yaounde, Cameroon.
    Kuaban C; Essame-Oyono JL; Lekama-Assiene T; Nlend R
    East Afr Med J; 1995 Oct; 72(10):672-4. PubMed ID: 8904051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer.
    Cha N; Li XY; Zhao YJ; Wang EH; Wu GP
    Clin Lung Cancer; 2012 Nov; 13(6):494-9. PubMed ID: 22464057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology. II. Diagnostic accuracy in equivocal smears.
    Motherby H; Friedrichs N; Kube M; Nadjari B; Knops K; Donner A; Baschiera B; Dalquen P; Böcking A
    Anal Cell Pathol; 1999; 19(2):59-66. PubMed ID: 10746435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignancies in Pleural, Peritoneal, and Pericardial Effusions.
    Dermawan JKT; Policarpio-Nicolas ML
    Arch Pathol Lab Med; 2020 Sep; 144(9):1086-1091. PubMed ID: 31913661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The immunocytochemical study of pleural effusion and ascites using Ber-EP-4 antibodies].
    Spehn J; Iwanetz S; Schmitz-Huebner U
    Dtsch Med Wochenschr; 1995 Sep; 120(36):1197-200. PubMed ID: 7671771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphoreticular malignancies in serous effusions: Cytomorphologic, flow cytometric and immunocytochemical analysis.
    Gupta P; Pandey T; Gautam U; Rajwanshi A; Srinivasan R; Gupta N; Rohilla M; Varma N; Dey P
    Diagn Cytopathol; 2021 May; 49(5):647-656. PubMed ID: 33629825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
    Lee WY
    Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
    Granados R; Cibas ES; Fletcher JA
    Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of FNAC in the management of salivary gland lesions: Institutional experiences leading to a risk-based classification scheme.
    Rossi ED; Wong LQ; Bizzarro T; Petrone G; Mule A; Fadda G; Baloch ZM
    Cancer Cytopathol; 2016 Jun; 124(6):388-96. PubMed ID: 26959289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.